Moderna is dialing back its plans for new vaccines, shelving several key projects as it grapples with a sharp slowdown in ...

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna's RSV vaccine, mRESVIA (mRNA-1345), has been approved ... particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Moderna MRNA announced a strategic overhaul and new financial guidance at its R&D day on Sept ... an economic moat and establish a portfolio of vaccines as well as oncology and rare-disease ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...